MNKD

SEC filing MNKD FDA Approves Afrezza for Kids 6+, Fulfills 2014 Postmarketing Requirement

4h ago

News MannKind gains FDA nod to expand inhaled insulin for children

3d ago

SEC filing MNKD FDA Releases Afrezza From Pulmonary Trial, Pediatric sBLA Under Review

5d ago

SEC filing MNKD Votes In: 9 Directors Elected, $142M Avg For; Advisory NEO Pay Backed By 137.3M Shares; Audit Firm Ratified With 221.1M For

10d ago

News Why MannKind Stock Tumbled on Thursday

14d ago

Insider trade Sale by David Thomson (EVP Genl Counsel & Secretary)

19d ago

Insider trade Sale by Steven B. Binder

19d ago

Scanner Large up move: 24.5% (2.2x normal daily movement)

25d ago

News MannKind drops after Q1 miss

26d ago

Scanner Large up move: 24.5% (2.2x normal daily movement)

26d ago

News MannKind CEO purchases 100,000 shares; stock climbs

83d ago

Insider trade Purchase by Michael Castagna (Chief Executive Officer)

83d ago

News MannKind hits 52-week low after Q4 earnings miss

95d ago

News Uniform Makers UniFirst, Cintas Renew Takeover Talks

112d ago

News MannKind Corporation (MNKD) Reveals 2026 Growth Drivers

134d ago

News MannKind Provides Business Updates and 2026 Growth Drivers

145d ago

News MannKind Corporation (MNKD) Secures FDA Approval for FUROSCIX Pediatric Use, Expanding Reach In Heart, Kidney Disease Care

152d ago

News Lantheus Exit: $28 Million Sale Comes as Earnings Fall 77% Year Over Year

153d ago

Scanner Unusual volume (z=6.0)

160d ago

Scanner Unusual volume (z=6.2)

161d ago

Scanner Unusual volume (z=6.2)

163d ago

Scanner Unusual volume (z=6.2)

164d ago

SEC filing MNKD Acquires scPharmaceuticals for $5.35/Share Cash Plus $1.00 Contingent Value Right

168d ago